Efficacy and Safety of Fremanezumab for the Preventive Treatment of Episodic Migraine in Children and Adolescents: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (PL5.001)
The SPACE study (NCT04458857) evaluated the efficacy, safety, and tolerability of fremanezumab in children and adolescents with episodic migraine (EM).
Authors
- Petra Bittigau (ORCID: https://orcid.org/0000-0002-6989-5223)
- Yael Carmeli Schwartz
- Piero Barbanti (ORCID: https://orcid.org/0000-0002-5670-3755)
- Sally Garnett
- Patricia Pozo‐Rosich (ORCID: https://orcid.org/0000-0003-0796-4702)
- Andrew D. Hershey (ORCID: https://orcid.org/0000-0002-1598-7536)
- Christina L. Szperka (ORCID: https://orcid.org/0000-0003-4786-8889)
- Juline Bryson
- Yoel Kessler
- Xiaoping Ning
- Steve Barash
Institutions
- Universitat Autònoma de Barcelona (ES)
- Cincinnati Children's Hospital Medical Center (US)
- Children's Hospital of Philadelphia (US)
- San Raffaele University of Rome (IT)
- Teva Pharmaceuticals (Israel) (IL)
- Teva Pharmaceuticals (United States) (US)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT)
- University of Cincinnati (US)
- Charité - Universitätsmedizin Berlin (DE)
- University of Pennsylvania (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211143
- Citations
- 4
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 5.88